Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Francis J. Giles(National University of Ireland), Dan Jones(The Ohio State University Wexner Medical Center), Rajyalakshmi Luthra, Srđan Verstovšek(Unknown), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Mary Beth Rios(The University of Texas MD Anderson Cancer Center), Moshe Talpaz(University of Michigan), N. Bekele(The University of Texas Health Science Center at Houston), Xian Zhou(The University of Texas Health Science Center at Houston)
Cited by 387
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k